Short-term outcomes of pediatric multiple sclerosis patients treated with alemtuzumab at a Canadian University multiple sclerosis clinic

There is a lack of literature documenting the use of alemtuzumab in pediatric multiple sclerosis (MS) patients. Here we describe a 16-year-old and a 17-year-old patient receiving alemtuzumab and being followed for 37 months and 20 months, respectively. Both patients experienced a 1.0 decrease in Exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Jure Hunt, David, Traboulsee, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333501/
https://www.ncbi.nlm.nih.gov/pubmed/32655877
http://dx.doi.org/10.1177/2055217320926613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7333501/
https://www.ncbi.nlm.nih.gov/pubmed/32655877
http://dx.doi.org/10.1177/2055217320926613

Ejemplares similares